Inclusion body myositis

Neurologic Clinics

Volumn 32, Issue 3, 2014, Pages 629-646

  Dimachkie, Mazen M ^a   Barohn, Richard J ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Diagnosis; Idiopathic inflammatory myopathies; Inclusion body myositis; Pathology; Pathophysiology; Polymyositis; Prognosis; Treatment

Indexed keywords

ALEMTUZUMAB; ANTINUCLEAR ANTIBODY; BETA CRYSTALLIN; BETA1A INTERFERON; CORTICOSTEROID; CREATINE KINASE; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; OXANDROLONE; SUCCINATE DEHYDROGENASE; THYMOCYTE ANTIBODY;

ARM WEAKNESS; BODY POSTURE; BULBAR PARALYSIS; CD8+ T LYMPHOCYTE; CREATINE KINASE BLOOD LEVEL; DEGENERATION; DYSPHAGIA; ELECTROMYOGRAPHY; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCLUSION BODY MYOSITIS; MUSCLE DISEASE; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN AGGREGATION; REVIEW; FEMALE; MALE; MYOSITIS, INCLUSION BODY; ONSET AGE; PATHOLOGY; SKELETAL MUSCLE;

AGE OF ONSET; FEMALE; HUMANS; MALE; MUSCLE, SKELETAL; MYOSITIS, INCLUSION BODY;

EID: 84904303158     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2014.04.001     Document Type: Review

References (77)

1. Phillips B.A., Zilko P.J., Mastaglia F.L. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve 2000, 23(6):970-972.
2. Tan J.A., Roberts-Thomson P.J., Blumbergs P., et al. Incidence and prevalence of idiopathic inflammatory myopathies in South Australia: a 30-year epidemiologic study of histology-proven cases. Int J Rheum Dis 2013, 16(3):331-338.
3. Lindberg C., Persson L.I., Bjorkander J., et al. Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurol Scand 1994, 89:123-131.
4. Wilson F.C., Ytterberg S.R., St Sauver J.L., et al. Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. JRheumatol 2008, 35(3):445-447.
5. Lotz B.P., Engel A.G., Nishino H., et al. Inclusion body myositis. Observations in 40 patients. Brain 1989, 112(Pt 3):727-747.
6. Badrising U.A., Maat-Schieman M.L., van Houwelingen J.C., et al. Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients. Neurology 2005, 252(12):1448-1454.
7. Amato A.A., Gronseth G.S., Jackson C.E., et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol 1995, 40:581-586.
8. Barohn R.J., Amato A.A. Inclusion body myositis. Curr Treat Options Neurol 2000, 2:7-12.
9. Badrising U.A., Maat-Schieman M., van Duinen S.G., et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 2000, 55:1385-1387.
10. Sayers M.E., Chou S.M., Calabrese L.H. Inclusion body myositis: analysis of 32 cases. JRheumatol 1992, 19:1385-1389.
11. Needham M., James I., Corbett A., et al. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. JNeurol Neurosurg Psychiatry 2008, 79(9):1056-1060.
12. Estephan B., Barohn R.J., Dimachkie M.M., et al. Sporadic IBM: a case cohort. JClin Neuromuscul Dis 2011, 12(3):18-19.
13. Hiscock A., Dewar L., Parton M., et al. Frequency and circumstances of falls in people with inclusion body myositis: a questionnaire survey to explore falls management and physiotherapy provision. Physiotherapy 2013, 100:61-65. pii:S0031-9406(13) 00073-4.
14. Goodman B.P., Liewluck T., Crum B.A., et al. Camptocormia due to inclusion body myositis. JClin Neuromuscul Dis 2012, 14(2):78-81.
15. Finsterer J., Stöllberger C., Kovacs G.G. Asymptomatic hyper-creatine-kinase-emia as sole manifestation of inclusion body myositis. Neurol Int 2013, 5(2):34-36.
16. Jethava A., Ali S., Dasanu C.A. Primary respiratory failure due to inclusion body myositis: think outside the box. Conn Med 2013, 77(3):155-158.
17. Barohn R.J., Amato A.A., Sahenk Z., et al. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology 1995, 45(7):1302-1304.
18. Ghosh P.S., Laughlin R.S., Engel A.E. Inclusion body myositis presenting with facial diplegia. Muscle Nerve 2013, 49:287-289. 10.1002/mus.24060.
19. Garlepp M.J., Laing B., Zilko P.J., et al. HLA associations with inclusion body myositis. Clin Exp Immunol 1994, 98:40-45.
20. Rothwell S., Cooper R.G., Lamb J.A., et al. Entering a new phase of immunogenetics in the idiopathic inflammatory myopathies. Curr Opin Rheumatol 2013, 25(6):735-741.
21. Amato A.A., Barohn R.J. Inclusion body myositis: old and new concepts. JNeurol Neurosurg Psychiatry 2009, 80(11):1186-1193.
22. Mercuri E., Pichiecchio A., Allsop J., et al. Muscle MRI in inherited neuromuscular disorders: past, present, and future. JMagn Reson Imaging 2007, 25(2):433-440.
23. Degardin A., Morillon D., Lacour A., et al. Morphologic imaging in muscular dystrophies and inflammatory myopathies. Skeletal Radiol 2010, 39(12):1219-1227.
24. Cox F.M., Reijnierse M., van Rijswijk C.S., et al. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology 2011, 50(6):1153-1161.
25. Amato A.A., Barohn R.J., Jackson C.E., et al. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1994, 44(8):1516-1518.
26. Wagner K.R., Fleckenstein J.L., Amato A.A., et al. Aphase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008, 63(5):561-571.
27. Glover G.H., Schneider E. Three-point Dixon technique for true water/fat decomposition with B0 inhomogeneity correction. Magn Reson Med 1991, 18(2):371-383.
28. Hiba B., Richard N., Hébert L.J., et al. Quantitative assessment of skeletal muscle degeneration in patients with myotonic dystrophy type 1 using MRI. JMagn Reson Imaging 2012, 35(3):678-685.
29. Maillard S.M., Jones R., Owens C., et al. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology (Oxford) 2004, 43(5):603-608.
30. Maetzler W., Reimold M., Schittenhelm J., et al. Increased [11C]PIB-PET levels in inclusion body myositis are indicative of amyloid beta deposition. JNeurol Neurosurg Psychiatry 2011, 82(9):1060-1062.
31. Chahin N., Engel A.G. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008, 70(6):418-424.
32. Van der Meulen M.F., Hoogendijk J.E., Moons K.G., et al. Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis. Neuromuscul Disord 2001, 11:447-451.
33. Greenberg S.A., Pinkus G.S., Amato A.A., et al. Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve 2007, 35(1):17-23.
34. Griggs R.C., Askanas V., DiMauro S., et al. Inclusion body myositis and myopathies. Ann Neurol 1995, 38(5):705-713.
35. Hilton-Jones D., Miller A., Parton M., et al. Inclusion body myositis: MRC centre for neuromuscular diseases, IBM workshop, London, 13 June 2008. Neuromuscul Disord 2010, 20(2):142-147.
36. Salajegheh M., Pinkus J.L., Taylor J.P., et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 2009, 40:19-31.
37. Dubourg O., Wanschitz J., Maisonobe T., et al. Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis. Acta Myol 2011, 30(2):103-108.
38. Greenberg S.A. Inclusion body myositis. Curr Opin Rheumatol 2011, 23(6):574-578.
39. Salajegheh M., Lam T., Greenberg S.A. Autoantibodies against a 43 kDa muscle protein in inclusion body myositis. PLoS One 2011, 6:e20266.
40. Greenberg S.A., Sanoudou D., Haslett J.N., et al. Molecular profiles of inflammatory myopathies. Neurology 2002, 59(8):1170-1182.
41. Greenberg S.A., Bradshaw E.M., Pinkus J.L., et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005, 65(11):1782-1787.
42. Larman H.B., Salajegheh M., Nazareno R., et al. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013, 73(3):408-418.
43. Pluk H., van Hoeve B.J., van Dooren S.H., et al. Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013, 73(3):397-407.
44. Askanas V., Engel W.K. Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology 2006, 66(2 Suppl 1):S39-S48.
45. Wojcik S., Engel W.K., McFerrin J., et al. Overexpression and proteasome inhibition increase alpha B-crystallin in cultured human muscle: relevance to inclusion-body myositis. Neuromuscul Disord 2006, 16(12):839-844.
46. Askanas V., Engel W.K. Sporadic inclusion-body myositis: conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-β42 oligomers and phosphorylated tau. Presse Med 2011, 40(4 Pt 2):e219-e235.
47. Salajegheh M., Pinkus J.L., Nazareno R., et al. Nature of "Tau" immunoreactivity in normal myonuclei and inclusion body myositis. Muscle Nerve 2009, 40(4):520-528.
48. Nogalska A., D'Agostino C., Engel W.K., et al. Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers. Acta Neuropathol 2010, 120(5):661-666.
49. Tawil R., Griggs R.C. Inclusion body myositis. Curr Opin Rheumatol 2002, 14:653-657.
50. Machado P., Brady S., Hanna M.G. Update in inclusion body myositis. Curr Opin Rheumatol 2013, 25(6):763-771.
51. Verma A., Bradley W.G., Ringel S.P. Treatment-responsive polymyositis transforming into inclusion body myositis. Neurology 2008, P060:19.
52. Benveniste O., Guiguet M., Freebody J., et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011, 134(Pt 11):3176-3184.
53. Dalakas M.C., Sonies B., Dambrosia J., et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997, 48:712-716.
54. Dalakas M.C., Koffman B., Fujii M., et al. Acontrolled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001, 56:323-327.
55. Zschüntzsch J., Voss J., Creus K., et al. Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and β-amyloid in the muscle. Arthritis Rheum 2012, 64(12):4094-4103.
56. Muscle Study Group Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis. Neurology 2001, 57:1566-1570.
57. Muscle Study Group Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology 2004, 63:718-720.
58. Badrising U.A., Maat-Schieman M.L., Ferrari M.D., et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002, 51:369-372.
59. Lindberg C., Trysberg E., Tarkowski A., et al. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 2003, 61:260-262.
60. Rutkove S.B., Parker R.A., Nardin R.A., et al. Apilot randomized trial of oxandrolone in inclusion body myositis. Neurology 2002, 58(7):1081-1087.
61. Barohn R.J., Herbelin L., Kissel J.T., et al. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology 2006, 66(2 Suppl 1):S123-S124.
62. Dalakas M.C., Rakocevic G., Schmidt J., et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009, 132(Pt 6):1536-1544.
63. Sancricca C., Mora M., Ricci E., et al. Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis. Neurol Sci 2011, 32(5):841-847.
64. Kosmidis M.L., Alexopoulos H., Tzioufas A.G., et al. The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study. JNeurol Sci 2013, 334:123-125. pii:S0022-510X(13)02856-6.
65. Murata K.Y., Kouda K., Tajima F., et al. Balloon dilation in sporadic inclusion body myositis patients with dysphagia. Clin Med Insights Case Rep 2013, 6:1-7.
66. Sanei-Moghaddam A., Kumar S., Jani P., et al. Cricopharyngeal myotomy for cricopharyngeus stricture in an inclusion body myositis patient with hiatus hernia: a learning experience. BMJ Case Rep 2013, 22:2013. pii:bcr2012008058.
67. Jackson C.E., Barohn R.J., Gronseth G., Muscle Study Group, et al. Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle Nerve 2008, 37(4):473-476.
68. Saperstein D.S., Levine T., Hank N., et al. Pilot trial of lithium treatment in inclusion body myositis. Neurology 2011, 76(Suppl 4):A106.
69. Pasquali L., Longone P., Isidoro C., et al. Autophagy, lithium, and amyotrophic lateral sclerosis. Muscle Nerve 2009, 40(2):173-194.
70. Wang Y, He J, McVey AL, etal. Twelve-month change of IBMFRS in the arimocolomol inclusion body myositis pilot study. Poster 7.255 at the American Academy of Neurology Annual Meeting. New Orleans, April 26, 2012.
71. Wang Y., He J., McVey A.L., et al. Twelve-month change of IBMFRS in the Arimocolomol Inclusion Body Myositis Pilot Study. Ann Neurol 2013, 74(Suppl 17):S95-S96.
72. Sekul E.A., Dalakas M.C. Inclusion body myositis: new concepts. Semin Neurol 1993, 13(3):256-263.
73. Cox F.M., Titulaer M.J., Sont J.K., et al. A12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 2011, 134(Pt 11):3167-3175.
74. Cortese A., Machado P., Morrow J., et al. Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials. Neuromuscul Disord 2013, 23(5):404-412.
75. Arnardottir S., Alexanderson H., Lundberg I.E., et al. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. JRehabil Med 2003, 35(1):31-35.
76. Johnson L.G., Edwards D.J., Walters S.B., et al. The effectiveness of an individualized, home-based functional exercise program for patients with sporadic inclusion body myositis. JClin Neuromuscul Dis 2007, 8:187-194.
77. Johnson L.G., Collier K.E., Edwards D.J., et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. JClin Neuromuscul Dis 2009, 10(4):178-184.